8-K: LadRx Regains Control of Aldoxorubicin Following Termination of License Agreement with NantCell

LadRx Corporation has regained control of its aldoxorubicin drug after mutually terminating its license agreement with NantCell, and has amended its royalty agreement with XOMA.

Summary

• LadRx Corporation has terminated its exclusive worldwide license agreement with NantCell for the development, manufacture, and commercialization of aldoxorubicin, effective June 3, 2024.
• The termination agreement releases both LadRx and NantCell from all continuing obligations, except for a 30-day discussion period regarding the potential purchase of aldoxorubicin inventory by LadRx.
• LadRx has amended its royalty purchase agreement with XOMA, which originally acquired royalty and milestone rights for aldoxorubicin in 2023.
• Under the amended agreement, if LadRx commercializes aldoxorubicin itself, it will pay XOMA a 1.5% royalty on net sales.
• If LadRx licenses aldoxorubicin to a third party, XOMA will receive 7.5% of royalty and milestone payments received by LadRx.
• The original royalty agreement with XOMA regarding arimoclomol remains unchanged.

Sentiment

Score: 7

Explanation: The document is generally positive as LadRx regains control of a key asset, but there are risks associated with taking on the full development costs. The amended royalty agreement with XOMA is a positive step, but it does mean a portion of future revenues will be shared.

Positives

• LadRx now has full control over the future development and commercialization of aldoxorubicin.
• The company has the option to purchase existing aldoxorubicin inventory, potentially accelerating its development plans.
• The amended royalty agreement with XOMA provides clarity on future financial obligations related to aldoxorubicin.
• LadRx retains the potential to benefit from the commercial success of aldoxorubicin, either directly or through licensing agreements.
• The company is actively reviewing the pre-clinical and clinical data for aldoxorubicin to determine the best path forward.

Negatives

• LadRx must now bear the full financial burden of developing and commercializing aldoxorubicin.
• If LadRx and NantCell do not reach an agreement on the inventory purchase, the disposition of the inventory will be at NantCell's discretion.
• The company will need to invest in further clinical development of aldoxorubicin.
• The amended royalty agreement with XOMA means that LadRx will have to share a portion of future revenues with XOMA.

Risks

• There is no guarantee that LadRx will be able to successfully commercialize aldoxorubicin.
• The company may face challenges in securing funding for the continued development of aldoxorubicin.
• The 30-day discussion period with NantCell may not result in an agreement for the purchase of the aldoxorubicin inventory.
• The company may face competition from other companies developing similar cancer therapeutics.
• The company's plans for LADR-7 may be impacted by the renewed focus on aldoxorubicin.

Future Outlook

LadRx will be reviewing the pre-clinical and clinical data for aldoxorubicin to determine the best path forward for its continued clinical development, and remains on track for filing an IND application for LADR-7 in the third or fourth quarter of 2024.

Management Comments

• Stephen Snowdy, PhD, CEO of LadRx, stated that they are excited to have aldoxorubicin back in-house.
• Dr. Snowdy noted that aldoxorubicin has shown lower cardiotoxicity compared to doxorubicin and has demonstrated promise in a Phase II trial.
• Dr. Snowdy also mentioned that they congratulate ImmunityBio on their recent successes and understand their focus on immunity-based products.

Industry Context

This announcement reflects a strategic shift for LadRx, moving from licensing its key asset to taking direct control of its development. This is not uncommon in the biotech industry, where companies often re-evaluate their strategies based on market conditions and internal capabilities. The termination of the agreement with NantCell suggests a change in priorities for both companies, with LadRx now focusing on its own development of aldoxorubicin.

Comparison to Industry Standards

• The termination of a licensing agreement and subsequent reacquisition of rights is not uncommon in the pharmaceutical industry, often driven by strategic shifts or changes in priorities.
• The royalty rates agreed upon with XOMA are within the typical range for early-stage pharmaceutical assets, with low-single-digit royalties for direct commercialization and mid-single-digit royalties for out-licensing.
• Companies like XOMA often specialize in acquiring royalty streams from biotech companies, providing upfront capital in exchange for a share of future revenues.
• The decision by LadRx to take direct control of aldoxorubicin development is similar to other biotech companies that choose to retain control of their key assets to maximize potential value.

Stakeholder Impact

• Shareholders may view the regaining of control over aldoxorubicin as a positive development, but will also be aware of the increased financial risk.
• Employees may be impacted by the shift in focus and resources towards aldoxorubicin.
• Customers (potential patients) may benefit from the continued development of aldoxorubicin.
• Suppliers may be impacted by changes in the supply chain for aldoxorubicin.
• Creditors may be impacted by the increased financial risk associated with the development of aldoxorubicin.

Next Steps

• LadRx will engage in discussions with NantCell regarding the purchase of aldoxorubicin inventory within a 30-day period.
• LadRx will review pre-clinical and clinical data for aldoxorubicin to determine the best path forward for its continued clinical development.
• LadRx will continue to advance LADR-7 towards the clinic, with an IND application expected in the third or fourth quarter of 2024.

Key Dates

Keywords

aldoxorubicin, LadRx, NantCell, XOMA, license agreement, royalty agreement, cancer therapeutics, biopharmaceutical, clinical development, commercialization